• Subjects voluntarily sign informed consent form;

• Males ≥ 18 years;

• Subjects are clinically diagnosed with severe hemophilia A;

• Have \> = 150 documented exposure days to a Factor VIII protein product

• No prior history of hypersensitivity or anaphylaxis associated with any FVIII immunoglobulin;

• Use a reliable contraception method during the study;

• Capsid antibody negative;

• Subjects have good compliance.